Loading clinical trials...
Loading clinical trials...
A Phase III, Multicentre, Double-blind, Prospective, Randomized, Placebo-controlled Study, Assessing the Efficacy and Safety of Dysport® Used for the Treatment of Lower-limb Spasticity in Adult Subjects With Hemiparesis Due to Stroke or Traumatic Brain Injury
Conditions
Interventions
Botulinum toxin type A
Placebo
Locations
62
United States
Mayo Clinic Arizona
Scottsdale, Arizona, United States
Rancho Los Amigos
Downey, California, United States
Pacific Neuroscience Medical Group
Oxnard, California, United States
Associated Neurologists of Southern CT, PC
Fairfield, Connecticut, United States
Parkinson's Disease & Movement Disorders Center of Boca Raton
Boca Raton, Florida, United States
Design Neuroscience
Miami Gardens, Florida, United States
Start Date
March 1, 2011
Primary Completion Date
December 1, 2013
Completion Date
May 1, 2014
Last Updated
September 28, 2022
Lead Sponsor
Ipsen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions